Ownership history in nVerses Capital, LLC Β· 5 quarters on record
This page tracks every 13F SEC filing in which nVerses Capital, LLC reported a position in TYRA BIOSCIENCES INC (TYRA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π nVerses Capital, LLC underperformed the S&P 500 by β42.0% annually on this TYRA position. Average cost basis: $23.51. Maximum drawdown during holding period: β60.4%.
β Significantly underperformed the S&P 500 by 42.0% ann.
4 quarters analyzed
Best entry: $23.51 (2024 Q3) Β· Worst: $23.51 (2024 Q3)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
1 add Β· 0 trims. Bought during 0 of 2 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size